Showing 118 of 118on this page. Filters & sort apply to loaded results; URL updates for sharing.118 of 118 on this page
Oculgen completes $30M Series B to advance first-in-class bispecific ...
Jayson Lee - Shenzhen Oculgen Biomedical Technology | 领英
Jack Chen - CEO of Shenzhen Oculgen Biomedical Technology Co., Ltd ...
Ocugen (NASDAQ:OCGN) Shares Up 1.5% - What's Next?
Ocugen Logo im transparenten PNG- und vektorisierten SVG-Format
Ocugen's Innovative Therapies on Display at BIO International 2024 ...
Ocugen's Strategic Moves Position Biotech Firm for Critical Regulatory ...
Ocugen Receives Key FDA Clearance to Advance Eye Disease Treatment ...
Ocugen plans two Phase I/II trials in macular disease - Clinical Trials ...
Ocugen announces FDA approval of Expanded Access Program for patients ...
Ocugen’s stock climbs as biotech company beats back investor claims on ...
Ocugen doses first patient in Phase 1/2 Clinical Trial evaluating ...
Ocugen's Financial Results Reveal Strategic Progress in Gene Therapy ...
Ocugen announces first patient dosed in Phase 1/2 clinical trial for ...
Ocugen's Strategic Push: Can the Biotech Firm Deliver on Its Ambitious ...
Ocugen Enters Agreement With Bharat Biotech to Commercialize Potential ...
FDA Clears Ocugen's Phase II/III Trial for Stargardt Disease Gene ...
Ocugen agrees to distribute Bharat Biotech's Covid-19 vaccine in the US
Ocugen - Meyer
Ocugen Applies for FDA Trial Approval of New COVID-19 Vaccine
Ocugen Raises $23 Million to Advance Ocular Gene Therapies - Global Genes
Ocugen (OCGN) - 3Q23 Reported With Several Products On Schedule To ...
Biotech Firm Ocugen Sets Ambitious Three-Year Regulatory Timeline ...
Ocugen Inc. (NASDAQ:OCGN) Announce Discontinuation Of Third Phase ...
OCGN Stock Tanks After Gene Therapy Trial Update — What Did Ocugen ...
Ocugen - Modifier Gene Therapy Platform Cutting-Edge Technology By ...
Bharat Biotech partner Ocugen to set up RnD centre in Hyderabad
Ocugen launches Ph3 trial for eye disease nanoemulsion - Drug Delivery ...
Ocugen expands Covaxin commercialization rights to include Canada
Ocugen Faces Critical Funding Timeline as Pipeline Advances - Stocks Today
Ocugen — Novel cell therapies for retinal diseases - Edison Group
Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory ...
Ocugen Provides Business Update with Third Quarter 2023 Financial ...
OCGN Share Price and News / Ocugen Inc (NASDAQ)
US-based Ocugen, Bharat Biotech collaborate - Telangana Today
Ocugen announces U.S. FDA cleared the IND amendment to initiate Phase 2 ...
Ocugen Showcases Innovative Gene Therapy Solutions at ARVO 2025 ...
Ocugen Inc. - Patient-Centric Biotechnology
Histogenics completes transformation into Ocugen with $7m deal for ...
Ocugen Inc (OCGN) Q1 2025 Earnings Call Highlights: Strategic Advances ...
Ocugen developing therapies for rare and underserved eye diseases ...
Ocugen wins FDA rare pediatric disease status for genetic eye disorder ...
Institutional Investors Increase Stakes in Biotech Firm Ocugen - Stocks ...
Ocugen Secures Validating Partnership for Gene Therapy Platform
Lawsuit Filed To Block Bharat Biotech's US Partner Ocugen From ...
FDA slaps another hold on Ocugen, Bharat's COVID vaccine after WHO ...
slide9
Ocugen Approaches Pivotal Juncture with Gene Therapy Pipeline | NewsCase
Ocugen Jumps After Vaccine Candidate Found 81% Effective - TheStreet
Ocugen doses first patient in Phase 3 liMeliGhT clinical trial for ...
Ocugen - Targeting 300,000 RP Patients with Gene-Agnostic Modifier ...
Ocugen: A Retinal Disease Juggernaut In The Making (NASDAQ:OCGN ...
Ocugen completes dosing in second cohort of GARDian clinical trial for ...
Ocugen touts Phase 2 data for eye disease gene therapy
(3) Ocugen Analysis
Ocugen Shares Surge on Promising Gene Therapy Trial Data
Ocugen Clinical Trial Could Lead to Breakthrough One-Time Treatment for ...
Ocugen CEO discusses on distributing Covid-19 vaccines to U.S.
List of U.S. FDA Approved Cell and Gene Therapy Products (38 ...
Ocugen Sees Ray of Light with Gene Therapy for Retinitis Pigmentosa
Ocugen Nears Critical Regulatory Milestone as Pipeline Advances
Ocugen Clinical Showcase Webcast Now Available! : r/Ocugen
Ocugen announced the dosing completion of subjects with Stargardt ...
[Video] Ocugen on LinkedIn: #covid19 #vaccines #genetherapy # ...
Ocugen posts midphase gene therapy data, charting course for rivalry ...
Ocugen doses first patient in phase 1 trial of OCU200 for treatment of ...
Ocugen initiates Phase 3 clinical trial for OCU400 gene therapy for ...
Ocugen logo in transparent PNG and vectorized SVG formats
Ocugen Signs Korean Licensing Deal for OCU400 as Gene Therapy Pipeline ...
Ocugen’s Strategic Vision: A 2026 Roadmap for Eye Disease Innovation
Gene Therapies | Ocugen, Inc.
Ocugen Shares Surge on Promising Gene Therapy Trial Results
Ocugen Announces Submission of Investigational New Drug to Initiate a ...
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit | INN
Ocugen signs licensing deal with South Korea's Kwangdong Pharmaceutical
Ocugen doses first patient in Phase 3 liMeliGhT clinical trial for OCU400
Ocugen - cleanline studio
Ocugen Shares Surge as Strategic Shift Renews Investor Confidence ...
Ocugen reports positive preliminary data from RP, LCA gene therapy trial
Ocugen Forges Strategic Alliance with Korean Pharma Giant - Stocks Today
We’re proud to support our clients at Ocugen as they continue pushing ...
Ocugen, Inc. (NASDAQ:OCGN) Q3 2023 Earnings Call Transcript
Ocugen eye disease gene therapy nabs underwhelming ph. 2 win
FDA clears Ocugen’s IND amendment for trial of Stargardt disease treatment
Aurora biotech raises $6 million | 9news.com
Ocugen Bolsters Leadership with Gene Therapy Expert Ahead of Pivotal ...
Ocugen, Inc. Q4 2025 Earnings Call Summary
Ocugen announces Health Canada approval to begin Phase 3 clinical trial ...
Ocugen Shares Surge on Analyst Optimism and Upcoming Clinical Catalysts ...
Competitive Threat Emerges for Ocugen’s Eye Disease Treatment
Ocugen - News, Articles etc. - European Pharmaceutical Review
Ocugen Aktie: Biotech-Hoffnung mit Rückenwind
Ocugen Shares Surge on Promising Mid-Stage Trial Data for Eye Disease ...
已投企业 | 欧科健荣获第十三届中国创新创业大赛生物医药全国赛成长组第三名 - 公司新闻 - 深圳市南山战略新兴产业投资有限公司
Our founder Jack Chen, has featured by AUT Ventures sharing the journey ...
Logo Us Biopharmaceutical Company Celgene Pictured Editorial Stock ...
5 ‘Strong Buy’ Biotechs That Can Double in 2018 | InvestorPlace
Optireach Technology & Scientific Approach for Eye Drop Drug - Oculis
聚乙二醇化生长激素 (安徽安科生物)(PEGylated recombinant somatropin(Anhui Anke ...
深圳欧科健生物医药科技有限公司 - 企查查
新药创制-元生创投
Five ophthalmology biotech companies to look out for
Efficacy of bi-specific antibody/OCUL101 and Eylea/PC by intravitreal ...
OCGN Stock - Ocugen, Inc Fundamental Technical Analysis Review - Martyn ...
Ocular Therapeutix is a Promising Biotech Company with Exciting ...
Swiss biotech Oculis raises $21m for nanoparticle eye-drops - Drug ...
Ocular Therapeutix eyeing sustained drug delivery - BioTuesdays
